Is occasional constipation on GLP-1 therapy dangerous?

Constipation itself is one of the most commonly reported adverse reactions in both drugs' clinical trials and is not, on its own, an emergency. It becomes a different category of concern when it progresses toward the specific warning signs below, which is why the FDA-approved labels distinguish routine constipation from ileus and intestinal obstruction as separate, more serious postmarketing reports.

What is ileus, and why is it listed on the GLP-1 label?

Ileus is when the intestines slow or stop moving contents through, and intestinal obstruction is a physical blockage. Both are listed under Postmarketing Experience in the FDA-approved labels for Wegovy and Zepbound. The FDA added an ileus warning to semaglutide's label in 2023 after reviewing postmarketing reports; Zepbound's label separately lists ileus, intestinal obstruction, and severe constipation including fecal impaction among reported adverse reactions.

Why do I need to tell my surgeon or dentist I'm on a GLP-1 drug before a procedure?

Because delayed gastric emptying means food and liquid can still be sitting in your stomach even after a normal pre-procedure fasting period, raising the risk of pulmonary aspiration under sedation or general anesthesia. Zepbound's FDA-approved label states this explicitly under Postmarketing Experience, and MedlinePlus's consumer drug information for semaglutide instructs patients to tell their doctor or dentist they are using the medication before any surgery, including dental surgery.

GLP-1 Constipation FAQ: Normal Side Effect vs. Medical Emergency

Q: Why does GLP-1 therapy cause constipation?

Semaglutide and tirzepatide both slow gastric emptying and intestinal transit as part of how they work, not as an unrelated side effect. In Wegovy's clinical trials, 24% of patients reported constipation versus 11% on placebo; in Zepbound's trials, constipation ranged from 11% to 17% depending on dose, versus 5% on placebo, according to the FDA-approved prescribing information for each drug.

Q: When does constipation cross the line into a reason to call your provider immediately?

MedlinePlus's consumer guidance for semaglutide lists 'severe stomach or intestinal problems' among the symptoms that warrant calling your doctor immediately or getting emergency care, alongside ongoing pain that starts in the upper abdomen and spreads to the back. Several days without a bowel movement, an inability to pass gas, or worsening abdominal bloating and pain fall into that category rather than something to manage on your own.

Why GLP-1 drugs cause constipation, what the FDA-approved labels actually say about ileus and intestinal obstruction, and why you need to tell your surgeon or dentist before any procedure with sedation.

Constipation comes up almost as often as appetite loss in the questions Houston GLP-1 patients bring to their clinics — and unlike appetite loss, it’s the one where the FDA-approved labels draw an explicit line between “expected side effect” and “call your doctor now.” That line is worth knowing before you’re the one deciding which side of it you’re on.

Why does GLP-1 therapy cause constipation?

Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) slow gastric emptying and intestinal transit as part of their mechanism — the same effect that blunts appetite also slows how quickly the gut moves things along. This isn’t a rare reaction: in Wegovy’s clinical trials, 24% of adult patients reported constipation, compared with 11% on placebo. In Zepbound’s trials, constipation was reported by 11% to 17% of patients depending on dose, compared with 5% on placebo. Both figures come directly from the FDA-approved prescribing information, in the adverse reactions tables each label publishes from its pivotal trials.

Is constipation on its own something to worry about?

No — on its own, it’s one of the most commonly reported effects of this drug class, not a red flag. The label data above already accounts for it as an expected outcome of slowed motility, not an unusual reaction. What changes the picture is not constipation existing, but constipation escalating, which is where the next two questions come in.

What is ileus, and why does the FDA label mention it separately?

Ileus is a slowdown or stoppage of normal intestinal movement; intestinal obstruction is an actual physical blockage. Both are distinct from routine constipation, and both are listed under Section 6.2, Postmarketing Experience, in the FDA-approved labels for Wegovy and Zepbound — the section where the FDA tracks adverse reports that come in after a drug is already on the market, separate from the rates measured in clinical trials. The FDA added the ileus warning to semaglutide’s labeling in 2023 after reviewing these postmarketing reports. Zepbound’s label goes further, separately listing “ileus, intestinal obstruction, severe constipation including fecal impaction” as reported adverse reactions. Neither label claims these are common, and neither establishes that the drug directly causes them — postmarketing reports are voluntary and don’t by themselves prove cause and effect. But their presence on the label is the FDA’s way of telling prescribers and patients to take a change from ordinary constipation to something more severe seriously.

Why does my clinic ask if I have a procedure coming up?

This is the part almost nobody expects. Zepbound’s FDA-approved label states, under Postmarketing Experience: “Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation.” Because these drugs delay gastric emptying, a standard overnight fast before a procedure may not be enough to guarantee an empty stomach — food or liquid can still be present, which raises the risk of aspiration under sedation. MedlinePlus’s consumer drug information for semaglutide injection is direct about the fix: “if you are having surgery, including dental surgery, tell the doctor or dentist that you are using semaglutide injection.” That instruction applies whether the procedure is a colonoscopy, a joint replacement, or a routine tooth extraction — any point where you’ll be sedated or put under general anesthesia.

When should constipation make you call your provider instead of waiting?

MedlinePlus lists “severe stomach or intestinal problems” among the symptoms serious enough to call your doctor immediately or seek emergency care, alongside ongoing pain that starts in the upper abdomen and spreads to the back. In practice, that means: several days without a bowel movement, an inability to pass gas, or abdominal bloating and pain that’s getting worse rather than better are reasons to call, not wait out. This is general information, not a diagnosis — a licensed prescriber who knows your history and can examine you is the one who can tell you whether what you’re experiencing is routine or not.

It’s also why we only list clinics with a named, NPI-verified prescriber: a question like “is this normal or do I need to be seen” needs someone reachable, not just a vial and a printed dosing schedule. Browse our verified GLP-1 and peptide clinics in Houston, read how we tell a legitimate clinic from the rest, and see our full verification standard. If you’re also navigating the appetite side of dose week, see our post-dose week FAQ on hunger and eating.

Sources: U.S. National Library of Medicine, DailyMed, “WEGOVY- semaglutide injection, solution” (FDA-approved prescribing information, Section 6.1 Clinical Trials Experience and Section 6.2 Postmarketing Experience), retrieved September 16, 2026. DailyMed, “ZEPBOUND- tirzepatide injection, solution” (Section 6.1 Clinical Trials Experience and Section 6.2 Postmarketing Experience), retrieved September 16, 2026. MedlinePlus (U.S. National Library of Medicine), “Semaglutide Injection”, last revised May 15, 2026, retrieved September 16, 2026.

This article is independent editorial content, not medical advice. See our medical disclaimer.